Featured Story | By Ben Adams Last month we found out, via Twitter, that AstraZeneca’s Charles Ferté, M.D., Ph.D., senior director and global project leader of oncology R&D, was leaving the Big Pharma, but we didn’t know for where. read more |
| |
|---|
|
Top Stories By Nick Paul Taylor Avrobio has updated its Fabry disease gene therapy R&D plans in light of the FDA’s conversion of Sanofi’s Fabrazyme to full approval. The conversion deprives Avrobio of the chance to seek accelerated approval using its current phase 2, leading the biotech to plan to pit AVR-RD-01 against Fabrazyme in a new head-to-head clinical trial. read more By Amirah Al Idrus As Roivant Sciences gears up its “next chapter,” the company is heading for the public markets by merging with a special purpose acquisition company, or SPAC, and raising $611 million in the process. read more Sponsored By: Mitotech S.A. Mitotech focuses its clinical development efforts on ophthalmology, hoping to deliver its mitochondria targeted therapies to patients suffering from age-related as well as rare genetic eye diseases. read more By Annalee Armstrong Affinia Therapeutics, a biotech developing adeno-associated virus vectors and gene therapies, has raked in $110 million through a series B financing to move its programs into the clinic. read more Sponsored By: Catalent Clinical Supply The COVID-19 pandemic has made society very aware of the need to be flexible in the approach to daily life. Use and acceptance of DTP has grown due to the pandemic, and sponsors quickly began to rethink their Direct-to-Patient (DTP) approach as patients increasingly requested that their study drugs be shipped to their homes. read more By Ben Adams Japanese pharma Astellas has culled a muscle disease research pact with Cytokinetics, two years after a partnered med between the two flopped in a midstage test. read more By Annalee Armstrong KalVista Pharmaceuticals will bring on Paul Audhya, M.D., as chief medical officer as the Cambridge, Massachusetts-based biotech works to get a clinical trial for its hereditary angioedema franchise back on track. read more By Nick Paul Taylor Enzyvant has sold its preclinical Farber disease therapy to Aceragen. NovaQuest Capital Management is funding the newly founded Aceragen, setting the biotech up to enter the clinic and go on to seek approval. read more By Conor Hale Built into a pair of glasses worn by the surgeon, a camera helps judge the alignment of instruments and the joint itself within their field of view, without requiring changes in conventional surgical techniques. read more By Eric Sagonowsky While the global sales rankings of Big Pharma's superstar drugs naturally feature the biggest names in the business, new meds often pop up or old drugs exit the scene. And the moves within the list from year to year illustrate many of the trends shaping pharma on a daily basis. read more Resources Sponsored By: Veeva Learn how to develop a standards program that has your full team’s buy-in and improves the efficiency and quality of your clinical trials. Sponsored By: ClearView Healthcare Partners As clinical treatment options become more patient-centric, digital therapeutics provide forward-looking biopharma players the opportunity to augment the value of their offerings to stakeholders. Sponsored By: Veeva One top 10 pharma outlines three key steps to launching a modular content strategy to generate localized content faster. Sponsored By: Blue Matter This 77-page e-book explores 7 keys to success that any biopharma company needs to keep in mind as it enters Europe. Sponsored by: Datacubed Health The average clinical trial spends $40,000 per patient. Yet despite these high costs, most trials struggle to retain patients. Sponsored By: AmerisourceBergen Developing a quality product and getting it approved for distribution is not enough to guarantee commercial success. Sponsored By: WCG Trifecta The new standards in study training help sponsors and CROs reduce costs by 60%, cut training time by 50%, and start enrollment 55 days faster – learn more today. Sponsored By: Oracle Health Sciences New research indicates an accelerated adoption of decentralized clinical trials due to COVID-19. Sponsored by: Cytiva A one-stop hub for Cytiva resources to support process intesification Sponsored By: August Bioservices How has COVID-19 impacted CRO/CDMO customer (dis)satisfaction and outsourcing decisions for pharma and biotech companies in 2021 and beyond? Sponsored by: Cytiva A one-stop hub for Cytiva resources to support process development and manufacturing of your novel molecule Sponsored by: PerkinElmer Informatics Discover the benefits of a cloud-native ELN that delivers better performance, security, connectivity, total cost of ownership PLUS sub-second search results through even the largest data volumes. Sponsored By: Within3 We enable virtual work — offering over-time sessions where participants are more focused, insights are more diverse and business goals are met. Sponsored by: TAC Roche has inked a $1.8 billion, all-cash deal for GenMark Diagnostics, to acquire its molecular tests designed to screen patient samples for multiple infections simultaneously. Sponsored By: Remarque Systems Remarque Systems consolidates data, then layers on visualization and automated metrics to generate consistent, actionable data insights in real-time. Click here for more info. Sponsored By: Culture Biosciences Find out how upstream bioprocess scientists can use Culture Biosciences’ bioreactor system and real-time data visualizations to get faster insights and get their product to market more quickly. Sponsored By: BC Platforms Those wishing to unlock RWD’s true value must have access to a variety of data sources/types and the technological capabilities to use the data to uncover meaningful insights. Sponsored By: Oracle Health Sciences New research indicates an accelerated adoption of decentralized clinical trials due to COVID-19. Sponsored by: Catalent Autologous cell therapies have seen propelled growth since 2017, with the spotlight on the first FDA approval of a chimeric antigen receptor (CAR) T cell immunotherapy, Kymriah® (tisagenlecleucel), for the treatment of relapsed/refractory B-cell acute lymphoblastic leukemia. Sponsored by: Catalent Learn about drug product process development challenges and risks, the difference between innovator and biosimilar drug product process development, and more during the drug product process development phase. Sponsored by: Catalent Get insights on key considerations for a successful tech transfer process for manufacturing a biologic drug product, including a case study on overcoming challenges in a process transfer for a sterile diluent. Sponsored by: Catalent In a BioPharma Dive industry survey, planning and forecasting were identified as top concerns for trial sponsors. In response to this need, the CSM team at Catalent has developed a methodology for identifying, evaluating, and proactively managing the inherent risks involved in clinical trial supply chain management. Sponsored by: Catalent Learn how to drive excellence within the forecasting process and utilize forecasting throughout the clinical study to better plan clinical supply budgets and project timelines. Explore how to identify potential supply-related issues before they can negatively impact your study. | 
.jpg)
